Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye
Overview
- Phase
- Not Applicable
- Intervention
- Triamcinolone
- Conditions
- Blind Painful Eye
- Sponsor
- Hospital Governador Celso Ramos
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- Changes in Pain intensity
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes.
Detailed Description
The management of chronic eye pain is a constant challenge to ophthalmology. Treatment varies with the intensity of pain, and topical eye drops and contact lens therapy are effective in many patients. In refractory cases, and without vision, surgical removal of the eye through enucleation is considered classical therapy. As less invasive alternatives we have cyclodestruction and neurolytic drug injection in order to promote analgesia for a prolonged period. The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of This is a prospective study of patients with blind painful eyes not responsive to topical treatment and with no indication for evisceration seen at the Department of Ophthalmology, Hospital Governador Celso Ramos (HGCR) in 2010.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients treated in the period at HGCR who wanted to be part of the protocol by signing the consent form
Exclusion Criteria
- •patients whose follow-up period was less than three months
Arms & Interventions
Intravitreal Triamcinolone
Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection
Intervention: Triamcinolone
Retrobulbar Chlorpromazine
Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection
Intervention: Chlorpromazine
Outcomes
Primary Outcomes
Changes in Pain intensity
Time Frame: 0, 1 month, 3 months, 6 months after procedure
Pain was measured asking the patient to graduate it in a scale from 0 to 10, 0 being no pain, 10 being the worst pain patient has experienced in life
Secondary Outcomes
- Changes in Use of eyedrops before and after drug injection(0, 1 month, 3 months, 6 months)
- Changes in Intraocular pressure (IOP)(0, 1 months, 3 months, 6 months)